No Non-Inferiority in Standard Regimen vs. Capecitabine for Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal The Oncologist, researchers have found that the continuous capecitabine regimen (Ccont) is not noninferior to the approved intermittent capecitabine regimen (Cint) for the treatment of patients with metastatic breast cancer.
The Cint regimen consists of capecitabine at a dose of 1,250mg/m2 twice daily for 2 weeks on and 1 week off versus the Ccont regimen that is capecitabine 800mg/m2 twice daily for each 21-day cycle.
For the study, researchers randomly assigned 195 patients with HER2/neu-negative metastatic breast cancer to either Cint or Ccont in order to assess noninferiority of Cint to Ccont.
Results showed that at 1 year, progression-free survival was 27.3% for the Cint group compared with 25.3% for the Ccont group (Difference = -2.0%; 95% CI: -15.5 - 11.5). This value exceeded the 15% deemed noninferior. No differences regarding efficacy were identified between the two groups. In regard to safety, hand-and-foot syndrome was observed in 41.1% of those treated with Cint versus 42.3% in Ccont.
The findings suggest that Ccont is not noninferior to the standard Cint for the treatment of women with metastatic breast cancer. The researchers note that further research should be conducted to improve hand-and-foot syndrome.
Capecitabine is not noninferior to approved intermittent capecitabine regimen for the treatment of metastatic breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer